We are live on ! Find out more
HP

Harbourvest Partners Portfolio holdings

AUM $101M
1-Year Est. Return 38.13%
This Fund
S&P 500
This Quarter Est. Return
+27.12%
1 Year Est. Return
-38.13%
3 Year Est. Return
-6.18%
5 Year Est. Return
-50.73%
10 Year Est. Return
+34.53%
AUM
$746M
AUM Growth
+$490M
Cap. Flow
+$474M
Cap. Flow %
63.58%
Top 10 Hldgs %
89.94%
Holding
50
New
24
Increased
–
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
W icon
Wayfair
W
+$313M
2
SNOW icon
Snowflake
SNOW
+$84.9M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$15.3M
4
RBLX icon
Roblox
RBLX
+$15.2M
5
RLAY icon
Relay Therapeutics
RLAY
+$12.9M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$10.2M
2
WORK
Slack Technologies, Inc.
WORK
+$2.58M
3
ADVM
Adverum Biotechnologies
ADVM
+$1.45M
4
PGNY icon
Progyny
PGNY
+$1.26M
5
MCRB icon
Seres Therapeutics
MCRB
+$795K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 45.86%
2 Technology 30.45%
3 Healthcare 19.21%
4 Communication Services 2.99%
5 Financials 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCT
26
DELISTED
Duck Creek Technologies, Inc. Common Stock
DCT
$655K 0.09%
+14,508
New +$699K
NET icon
27
Cloudflare
NET
$96B
$652K 0.09%
+9,278
New +$715K
OYST
28
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$625K 0.08%
+34,185
New +$717K
CTMX icon
29
CytomX Therapeutics
CTMX
$690M
$612K 0.08%
79,193
– –
CSLT
30
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$527K 0.07%
349,070
– –
SPT icon
31
Sprout Social
SPT
$530M
$502K 0.07%
+8,692
New +$545K
MRNS
32
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$479K 0.06%
+30,962
New +$448K
FROG icon
33
JFrog
FROG
$8.88B
$477K 0.06%
+10,756
New +$620K
TRVN
34
DELISTED
Trevena, Inc.
TRVN
$419K 0.06%
374
– –
KA
35
DELISTED
Kineta, Inc. Common Stock
KA
$399K 0.05%
3,147
– –
RPTX
36
DELISTED
Repare Therapeutics
RPTX
$377K 0.05%
+12,276
New +$417K
RAPT
37
DELISTED
RAPT Therapeutics
RAPT
$274K 0.04%
1,544
– –
PMVP icon
38
PMV Pharmaceuticals
PMVP
$57.1M
$253K 0.03%
+7,692
New +$303K
EPZM
39
DELISTED
Epizyme, Inc
EPZM
$215K 0.03%
24,686
– –
JNCE
40
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$205K 0.03%
+19,927
New +$218K
NXTC icon
41
NextCure
NXTC
$20.4M
$101K 0.01%
837
– –
METC icon
42
Ramaco Resources Class A
METC
$629M
$63K 0.01%
15,453
– –
AM icon
43
Antero Midstream
AM
$10.2B
$30K ﹤0.01%
+3,316
New +$28.6K
HNRG icon
44
Hallador Energy
HNRG
$646M
$27K ﹤0.01%
14,270
– –
ADVM
45
DELISTED
Adverum Biotechnologies
ADVM
– –
-13,415
Closed -$1.45M
AR icon
46
Antero Resources
AR
$10.9B
– –
-131,895
Closed -$719K
PGNY icon
47
Progyny
PGNY
$2.46B
– –
-29,743
Closed -$1.26M
TDOC icon
48
Teladoc Health
TDOC
$1.66B
– –
-50,943
Closed -$10.2M
XGN icon
49
Exagen
XGN
$105M
– –
-25,982
Closed -$343K
WORK
50
DELISTED
Slack Technologies, Inc.
WORK
– –
-61,037
Closed -$2.58M
1
2

Similar funds

VCM
Vines Capital Management Monroe, Louisiana $101M AUM
TCI
Triveni Capital Investments Stamford, Connecticut $101M AUM
RPC
Royal Palms Capital Whitefish, Montana $101M AUM
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $101M AUM
HWM
Hobbs Wealth Management Zionsville, Indiana $101M AUM 22.3% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
ROP
Rule One Partners Moreland, Georgia $101M AUM 6.3% 1-Year Est. Return

Harbourvest Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Harbourvest Partners held 50 positions worth $746M, up 191% from $256M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Harbourvest Partners deployed $474M of net new capital in Q1 2021, opening 24 new positions. Its largest new stake was Wayfair: 1,062,126 shares worth $334M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 46% of assets, up from 1% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Seres Therapeutics, an estimated $795K trimmed.

  • Harbourvest Partners's largest Q1 2021 buy was Wayfair: 1,062,126 shares worth $334M.
  • Harbourvest Partners's biggest Q1 2021 reduction was Seres Therapeutics, cutting an estimated $795K.
  • Harbourvest Partners fully exited Teladoc Health in Q1 2021, selling an estimated $10.2M.
  • Harbourvest Partners's ten largest holdings make up 90% of its $746M portfolio in Q1 2021.
  • Harbourvest Partners opened 24 new positions and closed 6 in Q1 2021.
  • Harbourvest Partners's portfolio value rose 191% quarter-over-quarter to $746M.

Based on Harbourvest Partners's 13F filing for Q1 2021, filed 17 May 2021.